Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:8 Number:613 ISSN#:2563-5476
Author Verified
ACE Report #5102
Ace Report Cover Tumour

Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095

Contributing Authors: PA Meyers CL Schwartz MD Krailo JH Healey ML Bernstein D Betcher WS Ferguson MC Gebhardt AM Goorin M Harris E Kleinerman MP Link H Nadel M Nieder GP Siegal MA Weiner RJ Wells RB Womer HE Grier Children's Oncology Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Dr. Paul A. Meyers discusses the addition of muramyl tripeptide to chemotherapy in the treatment of Osteosarcoma.


662 osteosarcoma patients without detectable metastatic disease were either randomized to three drug (cisplatin, doxorubicin, methotrexate) or four drug chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide). A further comparison was conducted on the effects of the addition muramyl tri-peptide (MTP) to both chemotherapy regimens. Four- and six-year evaluations of event free survival (...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.